Diagnostics

UCLA's Dr. Donald Kohn joins the Jeffrey Modell Foundation to discuss revolutionary gene therapies offering new hope for Primary Immunodeficiency patients.

Insight Molecular Diagnostics secures $26M to expand its transplant rejection test to the heart market, backed by a major shareholder amid market dilution concerns.

NervGen Pharma to unveil data showing its drug NVG-291 provides lasting functional gains for chronic spinal cord injury, a major step forward.

New research proves pocket-sized, AI-powered ultrasound is a game-changer for urgent care, tackling staff shortages and improving patient outcomes.

A major new report reveals a deepening crisis in rural healthcare, as a $50 billion federal program clashes with devastating cuts, pushing a vital system to the brink.

Laurie Ann Goldman, the branding guru who built SPANX, is now CEO of Audien Hearing. Can she make affordable hearing aids a mainstream wellness product?

ARS Pharma's neffy challenges the EpiPen with new data on efficacy, cost-effectiveness, and patient preference, promising a less intimidating allergy emergency.

With two high-profile board appointments, Stellaromics signals its ambition to dominate the 3D spatial omics market with its advanced Pyxa™ platform.

The advisory giant's acquisition of a Boston-based specialist signals a strategic push into the high-stakes, high-growth world of life sciences and biotech.

A groundbreaking partnership in Italy is creating an AI-powered biobank to transform cancer diagnosis, promising faster, more accurate results for patients.

A new IFPA and WHO Foundation partnership aims to revolutionize care for 100 million psoriasis sufferers, leveraging AI and updated global data.

A national report card gives the U.S. a 'B' on rare disease policy, but stark state-by-state disparities leave millions vulnerable to financial ruin.

The nation's top IV therapy franchise reports record growth, but its expansion highlights a booming wellness industry navigating a complex regulatory landscape.

Waters finalized its $18.8B merger with BD's units, doubling its size. But investor concerns over near-term performance sent shares tumbling.

Amid market volatility, Lavior is boosting US production and launching dual product lines, a strategic move to ensure stability for clinics and consumers alike.

Backed by a proven billion-dollar impact model, 14 new startups are using AI, neuroscience, and philanthropy to revolutionize mental healthcare.

A £500,000 philanthropic investment fuels five pioneering research projects at Oxford, aiming to unlock new treatments for a devastating rare disease.

Heart disease is the leading cause of premature death for Canadian women, yet it remains under-diagnosed and under-treated. A national movement is fighting back.

The Middle East healthcare giant posts record profits and a $163M dividend, fueled by aggressive international acquisitions and a major bet on AI technology.

Median Technologies' eyonis® LCS gains landmark FDA clearance, promising to revolutionize early detection of the deadliest cancer with its AI-powered diagnostics.